DrugPatentWatch Database Preview
Patent: 7,727,954
Summary for Patent: 7,727,954
| Title: | Drug depot implant designs |
| Abstract: | The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement. |
| Inventor(s): | McKay; William F. (Memphis, TN) |
| Assignee: | Warsaw Orthopedic, Inc. (N/A) |
| Application Number: | 11/734,618 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,727,954
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen | ZINBRYTA | daclizumab | INJECTABLE;INJECTION | 761029 | 001 | 2017-05-26 | Start Trial | Warsaw Orthopedic, Inc. (N/A) | 2026-04-13 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 125472 | 001 | 2013-10-21 | Start Trial | Warsaw Orthopedic, Inc. (N/A) | 2026-04-13 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 003 | 2010-01-08 | Start Trial | Warsaw Orthopedic, Inc. (N/A) | 2026-04-13 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 002 | 2010-01-08 | Start Trial | Warsaw Orthopedic, Inc. (N/A) | 2026-04-13 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Warsaw Orthopedic, Inc. (N/A) | 2026-04-13 | RX | search | |
| Abbvie Inc | HUMIRA | adalimumab | VIAL | 125057 | 002 | 2002-12-31 | Start Trial | Warsaw Orthopedic, Inc. (N/A) | 2026-04-13 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 7,727,954
| Country | Patent Number | Publication Date |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007121288 | Jul 17, 2008 |
| World Intellectual Property Organization (WIPO) | 2007121288 | Oct 25, 2007 |
| United States of America | 2007243225 | Oct 18, 2007 |
| United States of America | 2007243228 | Oct 18, 2007 |
| United States of America | 2010158800 | Jun 24, 2010 |
| United States of America | 2010189757 | Jul 29, 2010 |
| >Country | >Patent Number | >Publication Date |
